No abstract available.
Hyperplasia

There are some errors in the published article. The authors would like to make corrections in the original version of the article.

No abstract available.
Carcinoma, Squamous Cell* ; Cisplatin* ; Drug Therapy* ; Head* ; Neck*

No abstract available.

PURPOSE: The aim of this study was to evaluate the efficacy of periprostatic lidocaine injection according to lidocaine dose during transrectal ultrasound-guided prostate biopsy. MATERIALS AND METHODS: The subjects of this study were 92 patients who had undergone transrectal ultrasound-guided 12-core biopsy of the prostate. The patients were randomly assigned to three groups: group 1 (n=31, no lidocaine injection), group 2 (n=30, periprostatic injection of 10 ml 1% lidocaine), and group 3 (n=31, periprostatic injection of 20 ml 1% lidocaine). The patients were assessed for pain by use of a 10-point visual analogue scale (VAS) and for other complications after the procedure. RESULTS: The mean VAS scores of groups 1 through 3 were 0.93+/-0.89, 1.32+/-1.37, and 1.13+/-1.10, respectively. There were no statistically significant differences between the three groups. However, the mean VAS score of the biopsy pain was 5.0+/-1.48, 3.93+/-1.94, and 3.60+/-2.15, in the same groups, respectively, with statistically significant differences between group 1 and the other groups. Patients in groups 2 and 3 reported significantly less biopsy pain than did group 1 patients (p=0.004, 0.021), with no statistically significant difference in VAS score between groups 2 and 3 (p=0.533). With respect to post-biopsy complications, there were no significant differences in the incidence of hematuria, hematospermia, rectal bleeding, or infection among the three groups. CONCLUSIONS: Periprostatic injection of local anesthesia with lidocaine was associated with significantly less pain than in the absence of anesthesia. Furthermore, a 20-ml dose of lidocaine produced no better pain control than did a 10-ml lidocaine dose for prostate biopsy.
Anesthesia ; Anesthesia, Local ; Biopsy ; Hematuria ; Hemorrhage ; Hemospermia ; Humans ; Incidence ; Lidocaine ; Prostate

PURPOSE: The aim of this study was to evaluate the efficacy of periprostatic lidocaine injection according to lidocaine dose during transrectal ultrasound-guided prostate biopsy. MATERIALS AND METHODS: The subjects of this study were 92 patients who had undergone transrectal ultrasound-guided 12-core biopsy of the prostate. The patients were randomly assigned to three groups: group 1 (n=31, no lidocaine injection), group 2 (n=30, periprostatic injection of 10 ml 1% lidocaine), and group 3 (n=31, periprostatic injection of 20 ml 1% lidocaine). The patients were assessed for pain by use of a 10-point visual analogue scale (VAS) and for other complications after the procedure. RESULTS: The mean VAS scores of groups 1 through 3 were 0.93+/-0.89, 1.32+/-1.37, and 1.13+/-1.10, respectively. There were no statistically significant differences between the three groups. However, the mean VAS score of the biopsy pain was 5.0+/-1.48, 3.93+/-1.94, and 3.60+/-2.15, in the same groups, respectively, with statistically significant differences between group 1 and the other groups. Patients in groups 2 and 3 reported significantly less biopsy pain than did group 1 patients (p=0.004, 0.021), with no statistically significant difference in VAS score between groups 2 and 3 (p=0.533). With respect to post-biopsy complications, there were no significant differences in the incidence of hematuria, hematospermia, rectal bleeding, or infection among the three groups. CONCLUSIONS: Periprostatic injection of local anesthesia with lidocaine was associated with significantly less pain than in the absence of anesthesia. Furthermore, a 20-ml dose of lidocaine produced no better pain control than did a 10-ml lidocaine dose for prostate biopsy.
Anesthesia ; Anesthesia, Local ; Biopsy ; Hematuria ; Hemorrhage ; Hemospermia ; Humans ; Incidence ; Lidocaine ; Prostate

INTRODUCTION: Hydroxyapatite(HA) coating implant can accelerate osseointegration, however, there are many controversies. MATERIALS AND METHODS: This study examined the early osseointegration of two types of hydroxyapatite coated implants. Twelve adult male miniature pigs (Medi Kinetics Micropigs, Medi Kinetics Co., Ltd., Busan, Korea) were used in this study. In the implants placed in the mandible, a histomorphometric evaluation was performed to evaluate the bone-implant contact (BIC) ratio. RESULTS: The BIC ratio increased with time. TS III HA and Zimmer HA were not significantly different (P>0.05). At 8 weeks, the BIC of Zimmer HA was higher than TS III HA, but there was no significant difference (P>0.05). CONCLUSION: HA coated implants will accelerate early osseointegration.
Adult ; Durapatite ; Humans ; Kinetics ; Male ; Mandible ; Nitrogen Mustard Compounds ; Osseointegration ; Swine

PURPOSE: To investigate the safety and the efficacy of intravesical gemcitabine therapy, we prospectively studied intravesical gemcitabine instillation followed by Bacillus Calmette-Guerin(BCG) instillation for treating the patients who suffer from superficial bladder cancer, and the above method was then compared with conventional BCG instillation. MATERIALS AND METHODS: Between May 2005 and April 2007, a total of 84 patients were divided into Group I: the patients were treated with a 2-week course of gemcitabine(1,000mg/50ml, 2,000mg/50ml) followed by a conventional 6-week course of BCG, and Group II: the patients were treated by BCG instillation only. Gemcitabine was instilled immediately within 6 hours after complete trans-urethral resection of the bladder tumor (TURBT) and then this was repeated one week later. BCG instillation was started 2 weeks after TURBT. The complications, recurrence rates, progression rates and recurrence-free period(RFP) were analyzed in both groups. RESULTS: The treatment was well tolerated in all the patients. Most of the complications were self-limiting, and there was no significant difference between the two groups(p=0.379). The recurrence rates of the two groups were 25.6% and 26.7%, respectively(p=0.899). Yet the recurrence-free period(RFP) was significantly longer in Group I(p=0.021). The progression rates of the two groups were 2.6% and 6.7%, respectively(p=0.620). CONCLUSIONS: Intravesical gemcitabine instillation showed the effect to prolong the recurrence-free period for patients with superficial bladder cancer. Further long-term study will be needed.
Administration, Intravesical ; Bacillus ; Deoxycytidine ; Humans ; Mycobacterium bovis ; Prospective Studies ; Recurrence ; Urinary Bladder ; Urinary Bladder Neoplasms

OBJECTIVE: Severe hyponatremia is rare but constitute a true medical emergency since it has deleterious effects on the central nervous system. The etiology and clinical presentation of severe hyponatremia are diverse and nonspecific, furthermore, the optimal therapeutic approach is debatable at the present time. Therefore, the purpose of this study is to analyze the clinical manifestations of severe hyponatremic patients and to assess the outcomes with special reference to the rate of its correction. METHODS: This retrospective study analyzed the clinical course of 27 consecutive patients(pts) at a single medical center who presented with neurologic hyponatremic symptoms as well as a serum sodium (Na) concentration less than 125mEq/L. RESULTS: Of 27 hyponatremic patients, male to female ratio was almost equal, 13 to 14, and mean age was 67.1 years. The most common cause of hyponatremia was SIADH(11 pts, 40.7%), followed by hypovolemia(11 pts, 37.1%), and edema(4 pts, 14.8%). Hyponatremic neurologic symptoms included lethargy(33.3%), confusion with drowsy mentality (33.3%), dizziness(18.6%), and semicoma(7.4%), respectively. The rate of increase to a serum Na concentration to 125mEq/L during correction of hyponatremic averaged 0.56+/-0.49mEq/L/hr while the maximum increase in serum Na concentration during any period of the hospital course, mostly initial phase, averaged 0.69+/-0.63mEq/L/hr in all 27 pts, of whom 18 pts(66.7%) was less than 0.5mEq/L/hr, 3 pts from 0.5 to 1.0mEq/L/hr(11.1%), and 6 pts more than 1.0mEq/L/hr(22.2%). All 27 pts but one recovered from neurologic symptoms due to hyponatremia without neurologic sequale. Extrapontine myelinolysis with locked in condition was developed during the course of treating hyponatremia in a pts, of whom serum Na concentration before treatment was the lowest(92mEq/L) with the rate of correction to 125mEq/L by 1.26mEq/L/hr and the initial rate of correction within the first 6 hour by 3.17mEq/L/hr. No one died of hyponatremia itself during the course of its treatment but 3 deaths of 27 pts were attributed to the pts' severe underlying diseases. CONCLUSION: Surprisingly, these data revealed the relatively benign course of severe symptomatic hyponatremia. However, in assessing the outcome of severe symptomatic hyponatremia, the initial degree of hyponatremia as well as the rate of correction during its treatment, particularly the initial rate of correction within the first 6 hour, would be considered.
Central Nervous System ; Emergencies ; Female ; Humans ; Hyponatremia ; Male ; Myelinolysis, Central Pontine ; Neurologic Manifestations* ; Retrospective Studies ; Sodium

Heterotopic gastric mucosa in the upper esophagus is frequently found during endoscopic examination. Although most patients with heterotopic gastric mucosa of the upper esophagus, referred as inlet patch, are asymptomatic, symptomatic patients with complications resulting from this ectopic mucosa have also been reported. Acid secretion by the inlet patch has been suggested in some reports. We report a case of heterotopic gastric mucosa in the upper esophagus, with secretion of acid, demonstrated by continuous ambulatory pH monitoring, and the improvement of pharyngeal symptoms after the use of a proton pump inhibitor.
Adult ; Ambulatory Care ; Anti-Ulcer Agents/administration & dosage ; Case Report ; Choristoma/diagnosis* ; Esophageal Diseases/drug therapy ; Esophageal Diseases/diagnosis* ; Esophagoscopy ; Gastric Acid/secretion* ; Gastric Mucosa/secretion* ; Human ; Hydrogen-Ion Concentration ; Male ; Monitoring, Physiologic/methods ; Prognosis